Entinostat (a class I HDACi) treatment induced NK activation via increased MIC expression in tumor targets as well as enhanced NKG2D expression and ADCC-mediated lysis in primary human NK cells (65, 66). The gene discussed is KLRK1; the disease is neoplasm.